Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Stelitano

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial InfectionsMatteo Mori, Giovanni Stelitano, Anna Griego, et al.
European Journal of Medicinal Chemistry|January 3, 2024
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessusMatteo Mori, Mario Cocorullo, Andrea Tresoldi, et al.
International Journal of Molecular Sciences|September 9, 2023
Could the Oxidation of α1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients?Maura D'Amato, Monica Campagnoli, Paolo Iadarola, et al.
European Journal of Medicinal Chemistry|June 26, 2018
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agentsLaurent R Chiarelli, Matteo Mori, Daniela Barlocco, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|March 21, 2019
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agentsLaurent R Chiarelli, Matteo Mori, Giangiacomo Beretta, et al.
Pharmaceutics|February 25, 2023
Targeting Siderophore-Mediated Iron Uptake in <i>M. abscessus</i>: A New Strategy to Limit the Virulence of Non-Tuberculous MycobacteriaMatteo Mori, Giovanni Stelitano, Giulia Cazzaniga, et al.
Journal of Medicinal Chemistry|June 9, 2026
Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological EvaluationAnshul Mishra, Wen-Bin Yang, Tsu-Shao Liu, et al.
Journal of Medicinal Chemistry|March 3, 2025
Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis TherapyGiulia Cazzaniga, Matteo Mori, Anna Griego, et al.
Journal of Medicinal Chemistry|July 8, 2026
Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>Rasoul Tamhaev, Deborah Recchia, Monika Záhorszká, et al.
European Journal of Medicinal Chemistry|November 7, 2025
Advancing the antituberculosis activity of nitropicolinic acids and amidesAndrew M Thompson, Chen-Yi Cheung, Matthew B McNeil, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial InfectionsMatteo Mori, Giovanni Stelitano, Anna Griego, et al.
European Journal of Medicinal Chemistry|January 3, 2024
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessusMatteo Mori, Mario Cocorullo, Andrea Tresoldi, et al.
International Journal of Molecular Sciences|September 9, 2023
Could the Oxidation of α1-Antitrypsin Prevent the Binding of Human Neutrophil Elastase in COVID-19 Patients?Maura D'Amato, Monica Campagnoli, Paolo Iadarola, et al.
European Journal of Medicinal Chemistry|June 26, 2018
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agentsLaurent R Chiarelli, Matteo Mori, Daniela Barlocco, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|March 21, 2019
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agentsLaurent R Chiarelli, Matteo Mori, Giangiacomo Beretta, et al.
Pharmaceutics|February 25, 2023
Targeting Siderophore-Mediated Iron Uptake in <i>M. abscessus</i>: A New Strategy to Limit the Virulence of Non-Tuberculous MycobacteriaMatteo Mori, Giovanni Stelitano, Giulia Cazzaniga, et al.
Journal of Medicinal Chemistry|June 9, 2026
Dual SYK-HDAC Inhibitor Elicits Striking Efficacy against Acute Myeloid Leukemia: Rational Design, Synthesis, and Biological EvaluationAnshul Mishra, Wen-Bin Yang, Tsu-Shao Liu, et al.
Journal of Medicinal Chemistry|March 3, 2025
Nanoenabling MbtI Inhibitors for Next-Generation Tuberculosis TherapyGiulia Cazzaniga, Matteo Mori, Anna Griego, et al.
Journal of Medicinal Chemistry|July 8, 2026
Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>Rasoul Tamhaev, Deborah Recchia, Monika Záhorszká, et al.
European Journal of Medicinal Chemistry|November 7, 2025
Advancing the antituberculosis activity of nitropicolinic acids and amidesAndrew M Thompson, Chen-Yi Cheung, Matthew B McNeil, et al.
Pageof 4